Küleon Bioscience
Jason Greer has a diverse work experience starting in 2004 as a Co-Founder of Nova Biosource Fuel Inc., a biodiesel refining company. Jason then went on to work as a Co-Founder at Kuleon Bioscience, a drug discovery company, from 2021 to the present. In 2007, they joined DCM Limited as a Vice President, Business Development, where they played a key role in raising capital for technology companies. From 2010, they also worked as an Author, sharing their personal journey through cancer treatment in a book called "Very Much Better." In 2011, they co-founded GenUI, a software development and tech commercialization firm, where they served as Chairman and later as Co-Founder & President until 2022. Currently, they are the Managing Director of GeekWork, a division of GeekWire, where they connect tech talent to companies using GeekWire's brand and community connections.
Jason Greer completed a course on Oxford Blockchain Strategy at Saïd Business School, University of Oxford in 2018. Prior to that, from 1998 to 2003, they earned a Bachelor of Science (BS) degree in International Business and Business Marketing from the University of Hawaii at Manoa. Additionally, Jason Greer has a certification as a Merchant Marine Officer from the United States Coast Guard, although the specific dates of their education in this field are not provided.
This person is not in the org chart
This person is not in any teams
Küleon Bioscience
Küleon is a drug discovery company focused on developing novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders. We’ve created a proprietary portfolio of serotonin receptor ligands designed to target neurocircuit abnormalities in the brain that are responsible for difficult-to-treat disorders such as schizophrenia and depression. We have successfully identified several preclinical leads that have significantly improved agonism characteristics such as low-to-no hallucinogenic or cardiotoxic liability, as well as modified PK/PD profiles when compared to other known atypical antipsychotics and serotonergic drugs. Serotonergic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. This is because many of the current SSRIs and non-selective serotonin receptor agonists were not designed with an eye towards functional selectivity. Our novel compounds are designed for functional selectivity via biased signalling mechanisms, potentially enhancing their therapeutic effect and reducing unwanted side effects. Our proprietary molecular scaffolds and compounds are novel and patentable, providing us with a tremendous strategic foothold in the market as companies continue to explore novel mechanisms of action for targeting neuropsychiatric diseases and disorders. We are collaborating with some of the world’s leading academic researchers and key opinion leaders in the serotonergic and atypical antipsychotic drug development space. Please reach out if you would like learn more about the work we are doing with our collaborators!